KDR and lung carcinoma: Ramucirumab, a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, inhibits ligand-induced proliferation and migration of human endothelial cells towards the treatment of advanced or metastatic gastric and lung cancer with disease progression in combination with chemotherapy.